Skip to main content
Premium Trial:

Request an Annual Quote

Prodesse To Use Invitrogen LUX PCR Reagents in Molecular Diagnostics

NEW YORK (GenomeWeb News) – Prodesse has licensed Invitrogen’s LUX PCR reagents for use in molecular diagnostics, the companies said on Friday.
 
The agreement marks the first use of the LUX (Light Upon eXtension) PCR chemistries in diagnostic assays, the companies said.
 
Invitrogen said that the LUX reagents can be used in gene expression studies, biomarker analysis, and functional genomics experiments and enable users to examine multiple targets in one experiment.
 
Tom Shannon, president and CEO of Prodesse, said in a statement that the technology offers “significant design flexibility as well the tremendous advantage of conveying service rights that do not carry royalty burdens to end users."
 
Prodesse, based in Waukesha, Wis., develops analyte specific reagents used by CLIA-certified laboratories for detecting infectious disease pathogens. The company currently offers a range of products covering 33 organisms.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more